[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521806":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":50,"collaborators":24,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":24,"maxAge":61,"enrollmentInfo":62,"targetDuration":24,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Endeavor Health","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Calfactant (Infasurf)","EXPERIMENTAL","Neonate, 28-35 weeks gestation, less than 48 hours of age, with respiratory distress syndrome on CPAP \\> 30% oxygen will be given 3ml\u002Fkg of Calfacant",[13],"Drug: MIST surfactant",{"label":15,"type":10,"description":16,"interventionNames":17},"Poractant alfa (Curosurf)","Neonate, 28-35 weeks gestation, less than 48 hours of age, with respiratory distress syndrome on CPAP \\> 30% oxygen will be given 2.5ml\u002Fkg of Poractant alfa.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","MIST surfactant","Surfactant will be given via MIST while neonate is on CPAP",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Matthew Derrick","CONTACT","18475702920","mderrick@northshore.org",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Northshore University Healthsystem","RECRUITING","Evanston","Illinois","60201","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-87.69006,42.04114,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":49,"phoneExt":24,"email":30},"Matthew Derrick, mbbs","8475702920",{"type":51,"investigatorFullName":27,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Attending Neonatologist","100521806","phase-4-non-inferiority-trial-investigating-surfactants-administered-via-mist-100521806",false,"NCT06074380","Non Inferiority Trial Investigating Surfactants Administered Via MIST","Niftisurf","Inclusion Criteria:\n\n* Preterm infants 28-35 6\u002F7 weeks' gestation and less than 48 hours of age who have a clinical diagnosis of respiratory distress syndrome confirmed by a chest x-ray on nasal continuous positive airway pressure (NCPAP) and FiO2 ≥0.30\n\nExclusion Criteria:\n\n* Infants will be excluded if there is a congenital anomaly or an alternative cause for respiratory distress.\n* Infants who require emergent intubation will not be enrolled in the interventions.","ALL","48 Hours",{"count":63,"type":64},262,"ESTIMATED","INTERVENTIONAL",[67],"PHASE4","RESEARCH DESIGN Multicenter, randomized, controlled trial. RECRUITMENT Entry criteria Preterm infants 28-35 6\u002F7 weeks' gestation and less than 48 hours of age who have a clinical diagnosis of respiratory distress syndrome. Infants who are on NCPAP and FiO2 ≥0.30 will randomized to curosurf or infasurf via MIST.\n\nExclusion criteria Infants will be excluded if there is a congenital anomaly or an alternative cause for respiratory distress.\n\nBabies who require emergent intubation will not be enrolled in the interventions.\n\nParental Consent will be obtained prior to randomization.",[70],"Respiratory Distress Syndrome",[72,73,74],"Pulmonary Surfactant","CPAP","Neonate","2025-08-04",{"date":77,"type":78},"2025-08-07","ACTUAL",{"date":80,"type":78},"2024-01-01",{"date":82,"type":64},"2027-12-01",{"name":5,"class":6},1]